ClinicalTrials.gg
Active, not recruitingNCT04975997EXCALIBER-RRMMUpdated Apr 3, 2026

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3 interventional study of Dexamethasone and Daratumumab in Multiple Myeloma, sponsored by Celgene. Active, not recruiting at 259 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing iberdomide in Multiple Myeloma — 11 open to participants now, 24 under way, 3 of them phase 3. iberdomide · Multiple Myeloma.

Enrollment
2nd of 27
939 · median 75
Started
2022
with 6 others
Phase 3
3 of 27
1 open now
Primary completion
2027-11
later than 10 of 23 live
Registered
4th of 27
by date
Lead sponsor
2 of 27
Celgene

Among the 27 studies testing iberdomide in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 7 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 10 of the 23 other live ones, and was the 4th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

11 of the 27 studies testing iberdomide in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About iberdomide

iberdomide: first FDA approval 2026 (ZENBEXUS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing iberdomide in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Read the detailed description

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM). Approximately 200 patients randomized in stage 1 to one of three iberdomide dose levels of 1, 1.3, or 1.6 mg in combination with daratumumab and dexamethasone (Treatment Arms A1, A2, or A3), or to the DVd comparator arm (Treatment Arm B).

In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1 between 2 treatment arms:

  • Approximately 332 subjects will be randomized to receive Treatment Arm A (IberDd)
  • Approximately 332 subjects will be randomized to receive Treatment Arm B (DVd)

Participants in both treatment arms will continue to receive treatment until confirmed progressive disease (PD), unacceptable toxicity or withdrawal of consent. To ensure accuracy and completeness of the primary endpoint assessment of progression-free survival (PFS), participants who permanently discontinue study treatment for any reason, other than confirmed PD or withdrawal of consent, will continue to be followed for disease assessment.

The study will be conducted in compliance with International Council for Harmonisation (ICH) and Good Clinical Practices (GCPs).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Iberdomide
  • CC-220
  • Daratumumab
  • Darzalex Faspro
  • Bortezomib
  • Velcade
  • Dexamethasone
  • MM
  • Multiple Myeloma
  • RRMM
  • CELMoD
  • Cereblon Modulators
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of multiple myeloma (MM) and .
  • Received 1 to 2 prior lines of anti-myeloma therapy.
  • Must have documented disease progression during or after their last anti-myeloma regimen.
  • (ECOG) performance status score of 0, 1 or 2.

Exclusion criteria

Exclusion Criteria

  • Any condition that confounds the ability to interpret data from the study.
  • Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis.
  • Known central nervous system involvement with MM.
  • Prior therapy with iberdomide.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
939 participants (actual)

Study arms

  • Experimental
    Daratumumab in combination with Iberdomide and dexamethasone - Dose 1

    Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.

    Drug: Dexamethasone · Drug: Daratumumab · Drug: Iberdomide

  • Experimental
    Daratumumab in combination with Iberdomide and dexamethasone - Dose 2

    Drug: Dexamethasone · Drug: Daratumumab · Drug: Iberdomide

  • Experimental
    Daratumumab in combination with Iberdomide and dexamethasone - Dose 3

    Drug: Dexamethasone · Drug: Daratumumab · Drug: Iberdomide

  • Active comparator
    Daratumumab in combination with dexamethasone and bortezomib

    Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone

    Drug: Dexamethasone · Drug: Bortezomib · Drug: Daratumumab

Interventions

  • Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

  • Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

    Also known as: DARZALEX FASPRO

  • Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.

  • Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle

    Also known as: CC-220, BMS-986382

  • Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle

    Also known as: CC-220, BMS-986382

  • Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle

    Also known as: CC-220, BMS-986382

  • Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8

  • Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.

    Also known as: DARZALEX FASPRO

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS).

    Time frame: Up to approximately 5 years

  2. Minimal Residual Disease (MRD) negative Complete Response (CR) at any time

    To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of minimal residual disease (MRD) negative complete response (CR) at any time.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Overall Survival (OS)

    To evaluate clinical efficacy in terms of overall survival (OS) in participants with relapsed or refractory multiple myeloma (RRMM) treated with iberdomide, daratumumab, and dexamethasone (IberDd) compared to daratumumab, bortezomib, and dexamethasone (DVd).

    Time frame: Up to approximately 5 years

  2. Sustainability of Minimal Residual Disease (MRD) negativity

    To evaluate the sustainability of minimal residual disease (MRD) negativity.

    Time frame: Up to approximately 5 years

  3. Overall Response Rate (ORR)

    Calculated as percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for multiple myeloma.

    Time frame: Up to approximately 5 years

  4. Time to response (TTR)

    Time from randomization to the first documentation of response (PR or better).

    Time frame: Up to approximately 5 years

  5. Duration of Response (DoR)

    Time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 5 years

  6. Time to Progression (TTP)

    The time from randomization to the first documented disease progression.

    Time frame: Up to approximately 5 years

  7. Time to Next Treatment (TTNT)

    Time from randomization to the start of the next antimyeloma treatment.

    Time frame: Up to approximately 5 years

  8. Progression-free Survival 2 (PFS2)

    Time from randomization to progression on the next anti-myeloma treatment or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 5 years

  9. Safety

    Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment.

    Time frame: Up to approximately 5 years

  10. European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)

    Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ-C30.

    Time frame: Up to approximately 5 years

  11. European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)

    EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Mean changes from baseline in subscale scores in subject-reported health related quality of life outcomes and multiple myeloma-related symptoms as measured by the EORTC QLQ- MY20.

    Time frame: Up to approximately 5 years

  12. Recommended iberdomide dose for Stage 2

    Time frame: Up to approximately 1 year

  13. Area under the plasma concentration-time curve from time zero to tau (AUC(TAU))

    Time frame: Up to approximately 1 year

  14. Maximum plasma concentration (Cmax)

    Time frame: Up to approximately 1 year

  15. Time to maximum plasma concentration (Tmax)

    Time frame: Up to approximately 1 year

07

Study locations

259 sites
  • Local Institution - 035
    Hot Springs, Arkansas 71913, United States
  • Local Institution - 641
    Cerritos, California 90703-2679, United States
  • Local Institution - 681
    Fountain Valley, California 92708, United States
  • Local Institution - 047
    Los Angeles, California 90033, United States
  • Local Institution - 684
    Newport, California 92663, United States
  • Local Institution - 033
    New Haven, Connecticut 06511, United States
  • Local Institution - 029
    Fort Myers, Florida 33901, United States
  • Local Institution - 693
    Ocala, Florida 34471-6950, United States
  • Local Institution - 028
    St. Petersburg, Florida 33705, United States
  • Local Institution - 045
    Tamarac, Florida 33321-2909, United States
  • Local Institution - 034
    West Palm Beach, Florida 33401, United States
  • Local Institution - 685
    Weston, Florida 33331-3609, United States
  • Local Institution - 018
    Atlanta, Georgia 30322, United States
  • Local Institution - 640
    Elk Grove Village, Illinois 60007-3363, United States
  • Local Institution - 697
    Dyer, Indiana 46311-1596, United States
  • Local Institution - 040
    Louisville, Kentucky 40207, United States
  • Local Institution - 041
    Alexandria, Louisiana 71301-3841, United States
  • Local Institution - 682
    Baton Rouge, Louisiana 70808-4300, United States
  • Local Institution - 027
    Baton Rouge, Louisiana 70809-3675, United States
  • Local Institution - 698
    Baltimore, Maryland 21204-6826, United States
  • Local Institution - 014
    Bethesda, Maryland 20817, United States
  • Local Institution - 688
    Columbia, Maryland 21044-3128, United States
  • Local Institution - 010
    Boston, Massachusetts 02215, United States
  • Local Institution - 009
    Worcester, Massachusetts 01655, United States
  • Local Institution - 645
    Burnsville, Minnesota 55337-6749, United States
  • Local Institution - 031
    Kansas City, Missouri 64132, United States
  • Local Institution - 046
    Billings, Montana 59102-6746, United States
  • Local Institution - 015
    Summit, New Jersey 07901, United States
  • Local Institution - 691
    New York, New York 10016, United States
  • Local Institution - 039
    Durham, North Carolina 27705, United States
  • Local Institution - 038
    Cincinnati, Ohio 45220, United States
  • Local Institution - 037
    Cleveland, Ohio 44109, United States
  • Local Institution - 008
    Cleveland, Ohio 44195, United States
  • Local Institution - 036
    Columbus, Ohio 43214, United States
  • Local Institution - 680
    Tulsa, Oklahoma 74146-6236, United States
  • Local Institution - 043
    Portland, Oregon 97239, United States
  • Local Institution - 030
    Chattanooga, Tennessee 37404, United States
  • Local Institution - 021
    Nashville, Tennessee 37203, United States
  • Local Institution - 687
    Austin, Texas 78705-1165, United States
  • Local Institution - 695
    Houston, Texas 77025, United States
  • Local Institution - 642
    Newport News, Virginia 23606-3069, United States
  • Local Institution - 643
    Roanoke, Virginia 24014-2419, United States
  • Local Institution - 025
    Madison, Wisconsin 53705, United States
  • Local Institution - 080
    Ciudad Autanoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
  • Local Institution - 083
    Villa Elisa, Buenos Aires B1894, Argentina
  • Local Institution - 813
    Birtinya, Queensland 4575, Australia
  • Local Institution - 812
    Douglas, Queensland 4814, Australia
  • Local Institution - 803
    Adelaide, South Australia 5000, Australia
  • Local Institution - 806
    Bedford Park, South Australia 5042, Australia
  • Local Institution - 802
    Clayton, Victoria 3168, Australia
  • Local Institution - 809
    East Melbourne, Victoria 3001, Australia
  • Local Institution - 801
    Melbourne, Victoria 3004, Australia
  • Local Institution - 811
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 807
    West Perth, Western Australia 6005, Australia
  • Local Institution - 804
    Camperdown, 2050, Australia
  • Local Institution - 800
    Fitzroy, 3065, Australia
  • Local Institution - 808
    Garran, ACT 2605, Australia
  • Local Institution - 155
    Graz, 73013, Austria
  • Local Institution - 154
    Linz, 4010, Austria
  • Local Institution - 153
    Salzburg, 5020, Austria
  • Local Institution - 156
    Sankt Pölten, 3100, Austria
  • Local Institution - 150
    Vienna, 1090, Austria
  • Local Institution - 151
    Vienna, 1160, Austria
  • Local Institution - 172
    Bruges, 8000, Belgium
  • Local Institution - 174
    Brussels, 1200, Belgium
  • Local Institution - 056
    Curitiba, Paraná 80530-010, Brazil
  • Local Institution - 050
    Porto Alegre, Rio Grande do Sul 90460-030, Brazil
  • Local Institution - 058
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Local Institution - 051
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 054
    Jaú, São Paulo 17210-080, Brazil
  • Local Institution - 055
    São Paulo, São Paulo 05403000, Brazil
  • Local Institution - 053
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution - 057
    São Paulo, 01509-900, Brazil
  • Local Institution - 052
    São Paulo, 04537-080, Brazil
  • Local Institution - 111
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 103
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 112
    Surrey, British Columbia V3V 1Z2, Canada
  • Local Institution - 104
    Saint John, New Brunswick E2L 3L6, Canada
  • Local Institution - 110
    St. John's, Newfoundland and Labrador A1B3V6, Canada
  • Local Institution - 101
    Halifax, Nova Scotia B3H 1V7, Canada
  • Local Institution - 109
    Ottawa, Quebec K1H 8L6, Canada
  • Local Institution - 108
    Québec, Quebec G1J 1Z4, Canada
  • Local Institution - 107
    Saskatoon, Saskatchewan S7N-0W8, Canada
  • Local Institution - 141
    Changsha, Hunan 410013, China
  • Local Institution - 129
    Nanchang, Jiangxi 330008, China
  • Local Institution - 143
    Xi'an, Shaanxi 710004, China
  • Local Institution - 142
    Shanghai, Shanghai Municipality 200434, China
  • Local Institution - 145
    Taiyuan, Shanxi 030032, China
  • Local Institution - 144
    Wenzhou, Zhejiang 325000, China
  • Local Institution - 140
    Beijing, 100071, China
  • Local Institution - 139
    Beijing, 100191, China
  • Local Institution - 138
    Beijing, 100730, China
  • Local Institution - 126
    Changchun, 130021, China
  • Local Institution - 121
    Chaoyang District, 100020, China
  • Local Institution - 135
    Guangzhou, 510030, China
  • Local Institution - 136
    Guangzhou, 510060, China
  • Local Institution - 128
    Hangzhou, 310006, China
  • Local Institution - 120
    Hangzhou, Zhejiang, 310006, China
  • Local Institution - 127
    Harbin, 150081, China
  • Local Institution - 134
    Nanjing, 210029, China

Showing the first 100 of 259 sites across 31 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodriguez-Otero P, Maciag P, Hong K, Amatangelo M, Chen M, van de Donk NWCJ. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920. Epub 2025 May 10. PubMed 40346992 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Nov 2027, 64 months after the start.

Of 109 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 64 months is above that.

Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2021
First posted
Jul 26, 2021
StartActual
Jun 23, 2022
Primary completionEst.
Nov 16, 2027
CompletionEst.
Jun 25, 2032
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04975997
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jul 26, 2021
Start date
Jun 23, 2022
Primary completion
Nov 16, 2027 (estimated)
Completion
Jun 25, 2032 (estimated)
Last update
Apr 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iberdomide

Start the discussion